Core Viewpoint - The company is actively expanding its international market presence and has established localized sales and service networks in over ten key countries and regions, aiming to enhance its global competitiveness and brand influence in the pharmaceutical equipment sector [1][4]. Group 1: International Market Expansion - The company has strategically divided its global operations into five regional departments to strengthen its international sales and service capabilities [1]. - In 2024, the company expects to achieve over 1.2 billion in new export orders, with products entering high-end markets such as Europe [1][4]. - Major international pharmaceutical companies have initiated supplier audits for the company, indicating potential future collaborations [1]. Group 2: Order Delivery and Revenue Recognition - The manufacturing cycle for main products typically ranges from 3 to 9 months, with revenue recognition based on specific criteria for domestic and international orders [2]. - The impact of U.S. tariffs on the company's sales and supply chain is minimal, as exports to the U.S. constitute a small portion of overall revenue [2]. Group 3: Development in Specific Fields - The company has established a joint venture in the peptide synthesis equipment sector, with the subsidiary achieving sales and reporting total assets of approximately 15.61 million and a net loss of about 2.22 million for 2024 [3]. - The company is pioneering the development of smart pharmaceutical factories, focusing on integrating artificial intelligence into its production processes to enhance efficiency and user value [3].

Group 1: International Market Expansion - The company has established localized sales and service networks in over 10 key countries and regions, enhancing its international business localization strategy [2] - In 2024, the company achieved new export orders exceeding 1.2 billion, with products entering high-end markets in Europe [2] - The company has divided its global market into five regional departments to strengthen international sales and service responsiveness [2] Group 2: Order Delivery and Revenue Recognition - The manufacturing cycle for main products typically ranges from 3 to 9 months, with revenue recognition based on customer acceptance [3] - For domestic orders, revenue is recognized upon obtaining the customer's signed acceptance, while for international orders, it is recognized upon receipt of customs and shipping documents [3] Group 3: Impact of Tariffs and Supply Chain - The impact of U.S. tariffs on the company's sales is minimal, as exports to the U.S. constitute a very small portion of overall revenue [3] - The company has invested in self-research for core components, reducing reliance on U.S. imports, and can substitute with domestic or other imported brands [3] Group 4: Development in Peptide Field - In August 2023, the company established a joint venture in peptide synthesis equipment, with total assets of approximately 15.6 million and a net profit of about 5.3 million by the end of 2024 [3] Group 5: AI Integration in Business - The company is leading the pharmaceutical equipment industry in developing smart pharmaceutical factories, focusing on both hardware and software investments [3] - The strategy aims to enhance production capabilities through AI technology, improving user value [3]

证券代码：300358 证券简称：楚天科技 公告编号：2025-041 号 债券代码：123240 债券简称：楚天转债 楚天科技股份有限公司 关于完成董事会换届选举及聘任高级管理人员、财务总 监、董事会秘书、内审负责人、证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 楚天科技股份有限公司（以下简称"楚天科技""公司"）2025 年 5 月 29 日 召开 2024 年年度股东大会，审议通过了关于董事会换届选举的相关议案。本次 选举产生了 8 名非独立董事、5 名独立董事，与公司通过职工代表大会选举产生 的 1 名职工代表董事，共同组成公司第六届董事会。任职期限至本次股东会通过 之日起三年。 同日，公司召开第六届董事会第一次会议，审议通过了《关于选举公司第六 届董事会董事长、副董事长的议案》、《关于选举公司第六届董事会专门委员会委 员的议案》、《关于聘任公司高级管理人员的议案》、《关于聘任公司财务总监、董 事会秘书、内审负责人、证券事务代表的议案》。现将有关情况公告如下： 一、董事会换届选举情况 （一）董事选举情况 公司于 2025 年 5 ...

法律意见书 湖南启元律师事务所 关于楚天科技股份有限公司 2024年年度股东大会的 致：楚天科技股份有限公司 湖南启元律师事务所（以下简称"本所"）接受楚天科技股份有限公司（以下 简称"公司"）的委托，指派本所律师列席了公司 2024 年年度股东大会（以下简 称"本次股东大会"），对本次股东大会的召集和召开程序、出席会议人员及召集 人的资格、表决程序和表决结果的合法有效性进行现场律师见证，并发表本法律 意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）、《深圳证券交易所上市公司股东会网络投票实施细则（2025 年修订）》 等我国现行法律、法规、规范性文件以及《楚天科技股份有限公司章程》（以下简 称"《公司章程》"）的有关规定出具本法律意见。 本所律师声明如下： （一）本所律师根据本法律意见书出具日以前已经发生或者存在的事实，严 格履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证， 保证本法律意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准 确，不存在虚 ...

| 证券代码：300358 | 证券简称：楚天科技 公告编号：2025-039 号 | | --- | --- | | 债券代码：123240 | 债券简称：楚天转债 | 楚天科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会以现场投票和网络投票相结合的方式召开。 2、2025 年 4 月 29 日公司披露了《关于召开 2024 年年度股东大会的通知》，本次 股东大会无新增、更改、否决议案的情况。 3、本次股东大会议案 8、10 为特别决议事项，应由出席股东大会的股东（包括股 东代理人）所持表决权的 2/3 以上审议通过。议案 12、13 为累积投票提案。 4、为尊重中小投资者利益，提高中小投资者对公司股东大会决议的重大事项的参 与度，本次股东大会审议影响中小投资者利益的重大事项时对中小投资者的表决单独 计票，中小投资者指单独或者合计持有本公司 5%以上股份的股东以外的其他股东，且 不包括持有公司股份的董事、监事和高级管理人员。 一、会议召开及出席情况 1、会议召集人：公司董事会 2 ...

证券代码：300358 证券简称：楚天科技 公告编号：2025-040 号 二、审议通过《关于选举公司第六届董事会专门委员会委员的议案》 根据《上市公司治理准则》、《深圳证券交易所创业板股票上市规则》、《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律 法规、规范性文件及《公司章程》等相关规定，公司董事会下设审计委员会、提 名委员会、薪酬与考核委员会、战略委员会四个专门委员会。 会议选举出的公司第六届董事会专门委员会人员组成情况如下： 审计委员会：独立董事张少球先生（召集人）、独立董事王善平先生、职工 代表董事李浪女士。 债券代码：123240 债券简称：楚天转债 楚天科技股份有限公司 第六届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 楚天科技股份有限公司（以下简称"公司"）第六届董事会第一次会议于 2025 年 5 月 29 日在公司会议室召开。会议通知于 2025 年 5 月 29 日现场送达给全体 董事。本次会议由公司董事长唐岳先生召集，应出席董事 14 人，实际出席董事 14 人，公司非董事 ...

Group 1: Company Overview - Chutian Technology Co., Ltd. is a well-known supplier of intelligent pharmaceutical equipment and overall technical solutions, focusing on various fields including chemical drugs, raw materials, biological drugs, and traditional Chinese medicine [2] - The company has expanded into the medical beauty and cosmetics sectors as part of its development strategy [2] Group 2: Financial Performance - The company aims to achieve profitability in 2025 after a loss in the first quarter, with expectations to turn around by mid-year or the third quarter through improved operational efficiency [2] - In 2024, Romaco Group reported a revenue of €208.75 million, a 1.26% increase year-on-year, but a net profit decline of 91.08% [4] Group 3: Order and Revenue Recognition - Domestic main engine orders are recognized upon obtaining customer-signed installation acceptance certificates, while international orders are recognized upon obtaining customs declarations and bills of lading [3] - The manufacturing cycle for main products typically ranges from 3 to 9 months, with delivery influenced by customer site conditions and project progress [2] Group 4: Impact of Tariffs - The impact of U.S. tariffs on sales is minimal, as exports to the U.S. account for a very small portion of overall revenue [3] - The company has reduced reliance on direct imports from the U.S. by developing core components in-house and utilizing domestic or alternative imported brands [3] Group 5: International Market Expansion - The company has established localized sales and service networks in over 10 key countries and regions, enhancing its international competitiveness [5] - In 2024, domestic exports exceeded 1.2 billion, with products entering high-end markets in Europe [6] Group 6: New Products and Business Development - The company has made significant progress in the fields of peptides, medical beauty, and blood products, establishing a smart factory for beauty products [6] - Chutian Technology has set up a joint venture in peptide synthesis, with total assets of approximately ¥15.61 million and a net loss of ¥2.22 million in 2024 [6]

Group 1: Financial Performance and Goals - The company aims to achieve profitability by the second or third quarter of 2025, following a loss in the first quarter [2] - The target for the year is to turn losses into profits through improved operational efficiency and quality [2] Group 2: Order and Revenue Recognition - The typical manufacturing cycle for products ranges from 3 to 9 months, with revenue recognized upon customer acceptance of installation [2] - Domestic orders are confirmed based on the customer's signed acceptance of the installation [2] Group 3: Impact of Tariffs and Supply Chain - The impact of U.S. tariffs on sales is minimal, as exports to the U.S. constitute a small portion of overall revenue [3] - The company has a low dependency on direct imports from the U.S. and has developed self-sufficiency for core components [3] Group 4: International Business Development - In 2024, the company’s export orders exceeded 1 billion RMB for the first time, with significant growth in international markets [3] - The company has established sales service centers in over ten countries to enhance international business [3][4] Group 5: New Products and Business Expansion - The company has expanded its business into new sectors such as peptides, medical beauty, and blood products, achieving notable success [4] - The subsidiary, Chutian Huaton, has diversified its product offerings into emerging fields like wastewater treatment and new energy lithium batteries [4]

Group 1: Industry Trends - The global pharmaceutical equipment market has surpassed $50 billion in 2024 and is expected to exceed $80 billion by 2030, with a compound annual growth rate (CAGR) of approximately 6-8% [1] - The "14th Five-Year" Pharmaceutical Industry Development Plan supports the development of high-end pharmaceutical equipment, with "domestic substitution" becoming a market trend [1] - The demand for equipment is rapidly increasing due to the transformation and upgrading of the pharmaceutical industry, driven by the rise of innovative drugs, biopharmaceuticals, and personalized formulations [2] Group 2: Technological Advancements - The construction of smart pharmaceutical factories is accelerating, with the adoption of MES systems, SCADA systems, and intelligent robots [2] - Data traceability has become a core element of GMP compliance, necessitating automated recording, audit trails, and electronic signatures [2] - The National Medical Products Administration's draft for the revised Good Manufacturing Practice (GMP) for sterile drugs aims to enhance the quality of sterile drug production in China [2] Group 3: Market Dynamics - There is a rising demand for personalized, small-batch, and multi-variety production, particularly for oncology drugs and rare disease medications [2] - Chinese pharmaceutical equipment companies are increasingly achieving international quality standards, enabling them to compete with top global firms [3] - The Asia-Pacific region, especially China and India, along with Latin America and the Middle East, is becoming a new growth driver for the global pharmaceutical equipment market [3] Group 4: Company Performance and Strategy - The increase in contract liabilities is attributed to a rise in orders and corresponding prepayments, without significant changes to the company's credit policy [3] - The company aims to enhance its international market presence and improve the quality of domestic contracts to drive business growth [3] - The company is focused on cost reduction and efficiency improvement through product optimization, supply chain cost management, and enhanced production efficiency [3] Group 5: Financial Overview - As of December 31, 2024, Chutian Microbead reported total assets of ¥81,528,093.58, net assets of ¥44,136,789.35, revenue of ¥14,738,069.68, and net profit of ¥635,992.39 [4] - Chutian Siwei Kang reported total assets of ¥24,429,337.66, net assets of ¥18,291,639.27, revenue of ¥9,688,180.16, and net profit of ¥5,529,069.30 as of December 31, 2024 [4] - Chutian Siyoute reported total assets of ¥32,086,926.74, net assets of -¥38,928,231.79, revenue of ¥7,933,943.61, and a net loss of -¥22,328,736.00 as of December 31, 2024 [4]

Group 1 - The core viewpoint of the news is that Chutian Technology's stock has experienced a decline in both revenue and net profit, indicating potential challenges in its financial performance [1] - As of May 6, Chutian Technology's stock closed at 7.63 yuan, up 2.28%, with a latest price-to-book ratio of 1.08, marking a new low in 20 days and a total market capitalization of 4.504 billion yuan [1] - The company has seen a net outflow of main funds amounting to 1.4716 million yuan on May 6, with a total outflow of 13.0364 million yuan over the past five days, indicating a trend of capital withdrawal [1] Group 2 - Chutian Technology Co., Ltd. specializes in the research, design, production, sales, and service of pharmaceutical equipment, becoming a leading enterprise in the domestic pharmaceutical equipment industry and a well-known player globally [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 1.083 billion yuan, a year-on-year decrease of 22.19%, and a net profit of -8.5569 million yuan, a year-on-year decline of 59.00%, with a sales gross margin of 29.76% [1] - In comparison to industry averages, Chutian Technology's price-to-earnings ratio (TTM) is -10.23, while the industry average is 48.90, indicating a significant underperformance relative to peers [2]